Next Phase Newsletter

A leading pharmaceutical company headquartered in China with integrated R&D, manufacturing, marketing, sales and distribution capabilities. The firm operates as a subsidiary of a publicly traded pharmaceutical company. The firm has a strong pipeline in liver diseases, oncology, respiratory diseases and is one of the top pharmaceutical companies in China within these domains. In addition, the firm has strong interest in CNS diseases, metabolic diseases, etc. With extensive experience and successful records of in and out licensing and co-development ventures with oversea companies, the firm is interested in collaborating with oversea companies whose assets align with its current pipeline and areas of interest. The firm is open to a wide range of partnership and capital structures, including co-development, in/out-licensing, equity investments and acquisitions. The firm is interested in opportunities globally. 
 
The firm is interested in therapeutic assets that align with their areas of focus, which include liver diseases, oncology, respiratory disease, CNS disease, metabolic diseases. The firm is open to various modalities within therapeutics, with a particular emphasis on both large and small molecule drugs. The firm seeks assets ranging from pre-clinical to early-clinical stages (Phase I/Phase Ib), but is also open to considering later-stage assets that align well with their scope of interest. 
 
The firm does not have any specific requirement for the company and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A Venture Capital firm formed by a partnership between a Europe-based pharma and a US-based VC is currently looking to make seed and venture stage investments into companies ranging anywhere from $200K to $5 million initially and up to $8 million over the life of the investment. The firm is actively seeking investment opportunities throughout the United States and Europe and could make as many as 2-4 new investments over the next year.

The firm is focused on rare and orphan diseases that affect less than 200,000 people throughout the United States. Within this area the firm is open to therapeutics and diagnostics across a number of technology types including, antibodies, small molecules, stem cells, cell therapy, gene therapy, vaccines, molecular diagnostics, and genomics among others. The firm is interested in companies anywhere from pre-clinical through phase III of clinical trials and has no preference for platform or single asset companies. The firm is looking for companies with disease modifying products targeting with significant understanding of the disease pathology. The firm is not interested in biosimilars or generics.

The firm is looking for privately held companies with experienced management teams. The firm looks to act as a hands on investor and seeks board representation following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2019 and headquartered in the US invests in early-stage life science companies, typically in Series A, with a focus on companies with smaller capital requirements. Average check size is $8M USD but can range from $1M-15M USD. The firm typically leads rounds but can also participate in syndicates. Though the firm has not invested in a startup abroad, they are open to global opportunities.

The firm is interested in all sectors of life science, but 80% of their interest is drugs. The remaining 20% is focused on other life science verticals such as devices and diagnostics. Areas of interest include orphaned assets, promising data that could potentially be out-licensed but was overlooked, or nutraceutical products that are being developed into drugs. The firm is indication-agnostic, however, gravitates towards and prefers niche areas such as ophthalmology, rare diseases, dermatology, psychiatry, and cardiometabolic diseases. Ideally, the firm would like to fund proof-of-concept data.

The firm requires to take a board seat. The firm does not have strict company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm that specializes in early-stage in-human clinical biotech ventures are driven by a passion for groundbreaking scientific advancements that have potential to revolutionize healthcare. The firm works closely with global CROs especially those in Australia. Initial check sizes range between $100k-200k USD, which are used directly for the clinical trial, and once Phase 1b starts, the firm will continue to invest at every phase of the trials with check sizes ranging from $100k-1.5M USD. The firm is open to investing in global companies.

The firm invests in biotech companies starting at the in-human clinical trial phase. The firm is indication-agnostic and have worked with companies in CNS, oncology, cardiology, and more.

The firm prefers to take a board advisor seat or have an advisory standpoint as they like to be active investors that provide value. The firm likes to see companies with a robust IP strategy, management teams, and a clear long-term plan from an exit standpoint.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2016 with offices in US and China invests exclusively in healthcare companies (therapeutics, medical devices, digital health, and healthcare services). The firm typically invests $1-5M (USD) of equity capital with the ability to make follow-on investment. The fund aims to make at least 5 investments per year, but this is not a fixed number. In general, the firm participates in seed, series A and series B funding rounds. The firm looks at companies of all parts of the world and has a strong preference for companies that have market opportunities in the US, Europe and China. The firm’s China office can provide companies with the resources they need for successful market entry in Asian markets.

The firm looks at all sectors pertaining to healthcare, including biotech therapeutics, R&D services, diagnostics, medical devices, and digital health. While the firm’s focus is in early-stage companies, it takes a very opportunistic viewpoint. In therapeutics, the firm will look at products of all stages from pre-clinical to phase III, and is open to all indications. In terms of medical devices, the firm will consider both 510k and PMA devices. In addition, the firm will also consider products that are already on the market.

The firm is open to both public and private companies, and expects them to have an experienced management team with a strong exit strategy. The firm requires a board seat in all portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

The corporate venture arm of a leading global company well known for its food products and amino science businesses with over $10B revenue seeks to create social and economic value for the global community. The group is headquartered in Tokyo, Japan, with over 34,000 employees throughout the globe. The group is currently focused on 4 growth areas, which are healthcare, food & wellness, ICT, and green.

The CVC was launched in 2020 with the goal of furthering the development in the 4 aforementioned growth areas, and has a US office based in Palo Alto, CA. The firm seeks to make equity investments up to $4M in promising early-stage companies, in mostly Seed and Series A rounds, and will reserve funds for follow-on investments as well. The firm invests globally, with the CVC’s US operations seeking opportunities based in North America and Europe.

The firm is most interested in early-stage biotech companies developing therapeutics of novel modalities. In particular, the firm likes to see platform technologies. The firm is open to a wide range of modalities including small molecules, biologics (i.e. ADCs), oligonucleotides, cell and gene therapy. The firm is open to pre-clinical and early clinical stage companies.The firm is indication agnostic.

The firm is currently not seeking conventional medical device and diagnostics companies, but is open to exploring digital health technologies with a very opportunistic mandate.

The firm has no specific company or management team requirements. The firm is most interested in seeing novel science. The firm prefers to act as a co-investor and does not actively seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A leading Spanish pharmaceutical company with a global presence is focused on the research, development, and manufacturing of prescription drugs, healthcare products, and animal nutrition. The company seeks to partner with early-stage companies to enrich its current internal drug discovery pipeline and is open to various partnership structures, including co-development, in-licensing, and acquisition. The firm also makes equity investments, and is open to both leading and co-investing. A board or observer seat may be considered on a case-by-case basis. The company is geographically agnostic and open to considering opportunities globally.

The company seeks early-stage assets for its drug discovery pipeline. While small molecules are a primary area of focus, the firm is open to different types of assets, including peptides, antibodies, and platform technologies. However, software and materials are out of scope. The firm is open to all indications and modalities. In terms of development phases, the company is interested in assets ranging from pre-clinical to Phase I.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.